Virosomal hepatitis A vaccine (strain RG-SB). A preliminary review of its immunogenicity, protective efficacy and tolerability in at-risk populations

BioDrugs

Volumn 7, Issue 3, 1997, Pages 232-248

  Lea, Andrew P ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; FORMALDEHYDE; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIGEN;

ADULT; AGE; CELLULAR IMMUNITY; CHILD; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; GENDER; HEPATITIS A; HEPATITIS A VIRUS; HIGH RISK POPULATION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VIRUS; INJECTION PAIN; INJECTION SITE; PRIORITY JOURNAL; REVACCINATION; REVIEW; SEROCONVERSION; SPLENECTOMY; TRAVEL; VACCINATION; VIRUS STRAIN;

EID: 0030837706     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707030-00006     Document Type: Review

References (95)

1. Lemon SM, Jansen RW, Brown EA. Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine 1992; 10 Suppl. 1: S40-44
2. Siegl G, Weitz M. Pathogenesis of hepatitis A: persistent viral infection as basis of an acute disease? Microb Pathog 1993 Jan; 14: 1-8
3. Melnick JL. Properties and classification of hepatitis A virus. Vaccine 1992; 10 Suppl. 1: S24-6
4. Boughton CR. Hepatitis A vaccine. Med J Aust 1991 Oct 21; 155: 508-9
5. Hadler SC, McFarland L. Hepatitis in day care centers: epidemiology and prevention. Rev Infect Dis 1986 Jul-Aug: 8 (4): 548-57
6. Mishra L, Seeff LB. Viral hepatitis, A through E. complicating pregnancy. Gastroenterol Clin North Am 1992 Dec; 21 (4): 873-87
7. Steffen R, Kane MA, Shapiro CN, et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994 Sep 21; 272: 885-9
8. Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10 Suppl. 1: S15-6
9. Lemon SM. Inactivated hepatitis A vaccines. JAMA 1994 May 4; 271: 1363-4
10. Stapleton JT. Host immune response to hepatitis A virus. J Infect Dis 1995 Mar; 171 Suppl. 1: S9-S14
11. Forbes A, Williams R. Changing epidemiology and clinical aspects of hepatitis A. Br Med Bull 1990 Apr: 46 (2): 303-18
12. Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang 1994; 67 Suppl. 4: 8-11
13. Hift RJ, Simjee AE. Hepatitis A. S Afr Med J 1994 Aug; 84 (8): 526-9
14. Wagstaff AJ, Plosker GL, Balfour J. Inactivated hepatitis A vaccine (HM175 strain): a preliminary review of its immunogenicity, protective potential and tolerability in at-risk patients. Clin Immunother 1996; 6 (1): 68-88
15. Studer S, Joller-Jemelka HI, Steffen R, et al. Prevalence of hepatitis A antibodies in Swiss travellers. Eur J Epidemiol 1993 Jan; 9: 50-4
16. Steffen R, Gyurech D. Advances in hepatitis A prevention in travellers. J Med Virol 1994; 44 (4): 460-2
17. Steffen R, Gyurech D. Risk of hepatitis A in travellers. Vaccine 1992; 10 Suppl. 1: S69-72
18. Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. J Hepatol 1993; 18 Suppl. 2: S11-4
19. Chiang B, Lee S-D. Hepatitis A immunization in Southeast Asia. JAMA South East Asia 1994 Feb; 10: 7
20. National Advisory Committee on Immunization (NACI). Statement on the prevention of hepatitis A infections. Canada Communicable Disease Report 1994 Aug 30; 20-16: 133-43
21. Jilg W. Adult use of hepatitis A vaccine in developed countries. Vaccine 1993; 11 Suppl. 1: S6-8
22. Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992; 14: 580-6
23. Stokes Jr J, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 1945 Jan 20; 127 (3): 144-5
24. Bryan JP, Nelson M. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines. Arch Intern Med 1994 Mar 28; 154: 663-8
25. Burkhardt F, Glück R, Finkel-Jimenez B, et al. Hepatitis A-vaccines: a comparison between three methods of antigen presentation. Dev Biol Stand 1996; 86: 129-35
26. Gupta RK, Relyveld EH, Lindblad EB, et al. Adjuvants - a balance between their toxicity and adjuvanticity. Vaccine 1993; 11 (3): 293-305
27. Glück R. Liposomal presentation of antigens for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995: 325-45
28. Epaxal Berna. Virosomal vaccine against hepatitis A. Swiss Serum and Vaccine Institute, Berne, Switzerland. 1995: (Data on file)
29. Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. Nature 1974 Nov 15: 252: 252
30. Bergers JJ, ten Hagen TLM, van Etten EWM, et al. Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm World Sci 1994; 17 (1): 1-11
31. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotech 1995; 13: 527-37
32. Gregoriadis G. The immunological adjuvant and vaccine carrier properties of liposomes. J Drug Targeting 1994; 2: 351-6
33. Tan LSK. Liposomes as antigen vehicles to increase immunogenicity: effects of structural characteristics. Ann Acad Med Singapore 1991; 20 (1): 78-83
34. Glück R. Liposomal hepatitis A vaccine and liposomal multiantigen combination vaccines. J Liposome Res 1995; 5 (3): 467-79
35. Gluck R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 1992; 10: 915-9
36. Glück R, Mischler R, Brantschen S, et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 1992 Dec; 90: 2491-5
37. Gregoriadis G, Florence AT. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993; 45 (1): 15-28
38. Wassef NM, Alving CR, Richards CR. Liposomes as carriers for vaccines. Immunomethods 1994; 4: 217-22
39. Mengiardi B, Berger R, Just M, et al. Virosomes as carriers for combined vaccines. Vaccine 1995 Oct; 13: 1306-15
40. Just MM, Berger RM, Mengardi BB, et al. Alum-free liposome-vaccine with multiple antigens by IRIV technique [abstract]. 34th ICAAC. Orlando, Florida, USA. Oct 1994
41. Alving CR. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann N Y Acad Sci 1995 May 31; 754: 143-52
42. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56: 365-94
43. Jackson DC, Crabb BS, Poumbourios P, et al. Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuruminidase and the trimer of influenza virus hemagglutinin. Arch Virol 1991; 116: 45-56
44. Taylor AH, Haberman AM, Gerhard W, et al. Structure-function relationships among highly diverse T cells that recognise a determinant from influenza virus hemagglutinin. J Exp Med 1990; 172: 1643-51
45. Matlin KS, Reggio H, Helenius A, et al. Infection entry pathway of influenza virus in a canine kidney cell line. J Cell Biol 1981; 91: 601-13
46. Roitt I. Essential Immunology. 8th ed. Oxford, UK: Blackwell, 1994
47. Neefjes JJ, Stoolorz V, Peters PJ, et al. The biosynthetic pathway of MHC class II molecules hut not class I molecules intersected the endocytotic route. Cell 1990; 61: 171-83
48. Air G, Laver WG. The neuraminidase of the influenza virus. Protein Struct Funct Genet 1989; 6: 341-56
49. Garçon NM, Six HR. Universal vaccine carrier. Liposomes that provide T-dependent help to weak antigens. J Immunol 1991; 146: 3697-702
50. Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine. Lancet 1994 Feb 5; 343: 322-4
51. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A-vaccine (abstract]. IX Triennial International Symposium on Viral Hepatitis and Liver Disease. 1996, Apr 21-25; Rome. Italy
52. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A-vaccine. Vaccine submitted
53. Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, et al. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995 Jul; 13: 891-3
54. Bovier P, Loutan L, Herzog C, et al. Virosome hepatitis A vaccine: 3 years of clinical experience [abstract]. Schweizerische Gesellschaft für Tropenmedizin und Parasitologie/Société Suisse de Médecine Tropicale et de Parasitologie. Annual Congress; 1995 Nov; Sarnen, Switzerland
55. Wiens BL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with Vaqta®. J Med Virol 1996; 49: 235-41
56. Herzog C, Wegmüller B. Epaxal Berna®: Duration of booster vaccination based on calculations with individual subject data. GMTs and median titer values up to 3 years post-booster. Swiss Serum and Vaccine Institute, Berne, Switzerland. (Data on file)
57. Herzog C, Angst F, Beck BR, et al. Safety and immunogenicity of a booster dose of a virosomal hepatitis A vaccine in healthy travellers after basic immunization with an alum-based hepatitis A vaccine [abstract]. Schweizerische Gesellschaft für Tropenmedizin und Parasitologie/Société Suisse de Médecine Tropicale et de Parasitologie. Annual Congress; 1995 Nov; Sarnen, Switzerland
58. Bovier P, Loutan L, Farinelli T, et al. Cross-immunogenicity and tolerance of two inactivated vaccines against hepatitis A virus [abstract]. European Conference on Tropical Medicine. 1995, Oct 22-26; Hamburg, Germany
59. Holzer BR, Hatz C, Schmidt-Sissolak D, et al. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 1996; 14 (10): 982-6
60. Just M, Berger R, Drechsler H, et al. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only 2 weeks. Vaccine 1992; 10 (11): 737-9
61. Herzog C, Wegmüller B. Hepatitis A vaccine Epaxal®: Open trial to determine immunogenicity and safety in healthy children aged 1 to 18 years in Valdivia, Chile. Swiss Serum and Vaccine Institute, Berne, Switzerland. (Data on file)
62. Bovier P, Loutan L, Althaus B, et al. Inactivated virosome hepatitis A vaccine: effect on the immune response of simultaneous vaccination against yellow fever [abstract]. Conference on Tropical Medicine and Parasitology; 1993 Sep-Oct; Konstant, Switzerland
63. Frösner GG, Dathe O, Althaus B, et al. High immunogenicity and low side effects of a new type of liposome vaccine against hepatitis A [in German]. In: Maass G, Stück B, editors. Virus-hepatitis A bis E - Diagnose, Therapie, Prophylaxe; Kongress-berichte des Deutschen Grunen Kreuss. Marburg: Kilian Verlag, 1994: 222-4
64. Frösner G, Dathe O, Althaus B, et al. Experience with virosomal hepatitis A vaccine [abstract no. 276]. 3rd Conference of International Travel Medicine. 1993; Paris, France
65. Simmen HP, Robustelli L, Althaus B, et al. Immune response to a single dose of a new type of hepatitis A vaccine in patients with splenectomy [in German]. Dtsch Med Wochenschr 1996 Mar 8: 121: 295-8
66. Berger R, Just M, Althaus B. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used. J Virol Methods 1993 Aug; 43: 287-98
67. Mayorga Perez O, Egger M, Frösner G. Placebo-controlled field efficacy trial of virosome formulated hepatitis A vaccine (Epaxal Berna®) among children in Nicaragua. Swiss Serum and Vaccine Institute; Bern, Switzerland; 1996. (Data on file)
68. Mayorga O, Egger M, Frösner G, et al. KV 9407: placebo controlled field efficacy trial of virosome formulated hepatitis A vaccine (Epaxal Berna®) among children in Nicaragua [abstract]. Swiss Serum and Vaccine Institute, Berne, 1996. (Data on file)
69. Hepatitis Surveillance Report No.55. Atlanta. Centers for Disease Control and Prevention, 1994
70. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, editors. Viral hepatitis and liver disease: proceedings. Baltimore: Williams and Wilkins, 1991: 14-20
71. Gutersohn T, Steffen GR, Van Damme P, et al. Hepatitis A infection in aircrews: risk of infection and cost-benefit analysis of hepatitis A vaccination. Aviat Space Environ Med 1996; 67 (2): 153-6
72. Tormans G, Van Damme P, Van Doorslaer E. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine 1992; 10 Suppl. 1: S88-92
73. Tormans G, Van Damme P, Van Doorslaer E. Recommendations for prevention of hepatitis A based on a cost-effectiveness analysis. J Travel Med 1994; 1 (3): 127-35
74. Behrens RH, Roberts JA. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A. and typhoid in travellers. BMJ 1994 Oct 8; 309: 918-22
75. Severo CA, Fagnani F, Lafuma A. Cost effectiveness of hepatitis A prevention in France. Pharmacoeconomics 1995 Jul; 8: 46-61
76. Jefferson TO, Behrens RH, Demicheli V. Should British soldiers be vaccinated against hepatitis A? An economic analysis. Vaccine 1994 Nov; 12 (15): 1379-83
77. Jefferson T, Demicheli V, Wright D. An economic evaluation of the introduction of vaccination against hepatitis A in a peacekeeping operation. The case of the United Nations Protection Force in Yugoslavia. Int J Technol Assess Health Care 1994; 10: 490-7
78. Van Doorslaer E, Tormans G, Van Damme P. Cost-effectiveness analysis of vaccination against hepatitis A in travellers. J Med Virol 1994 Dec; 44: 463-9
79. Swiss Serum and Vaccine Institute, Bern, Switzerland 1996. (Data on file)
80. Van Doorslaer E, Tormans G, Van Damme P, et al. Cost effectiveness of alternative hepatitis A immunisation strategies. Pharmacoeconomics 1995; 8 (1): 5-8
81. Hardie R. Vaccination against hepatitis A tor travellers. All relevant costs and consequences should be measured [letter]. BMJ 1995 Jan 7; 310: 61-2
82. Adler R, Shouval D. Hepatitis A prophylaxis: vaccine or immunoglobulin? Clin Immunother 1996; 6 (4): 261-72
83. Prescribing information. Hepatitis A vaccine, inactivated Havrix®. SmithKline Beecham Pharmaceutical, Philadelphia, USA 1995
84. Vaqta™ Hepatitis A vaccine, purified inactivated. Drugs Future 1995; 20 (1): 24-9
85. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996 Apr 5; 272: 54-60
86. Merck Vaqta hepatitis A vaccine to be launched in May. FDC Rep Pink Sheet 1996 Apr 1: 13
87. Langer BCA, Lövestad A, Frösner CG. High immunogenicity and good tolerability of a new hepatitis A vaccine candidate. Vaccine 1996; 14 (12): 1089-91
88. Fisch A, Cadilhac P, Vidor E, et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 1996; 14 (12): 1132-6
89. Garin D, Vidor E, Wallon M, et al. Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults. Vaccine 1995; 13 (2): 220-4
90. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995; 73: 15-20
91. Margolis HS, Shapiro CN. Considerations for the development of recommendations for the use of hepatitis A vaccine. J Hepatol 1993; 18 Suppl. 2: S56-60
92. Hollinger FB, Eickhoff T, Gershon A, et al. Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States. J Infect Dis 1995 Mar; 171 Suppl. 1: S73-77
93. Brewer MA, Edwards KM, Decker MD. Who should receive hepatitis A vaccine? Pediatr Infect Dis J 1995 Apr; 14: 258-60
94. Bader TF. Hepatitis A vaccine. Am J Gastroenterol 1996; 91 (2): 217-22
95. Cadilhac P, Roudot-Thorval F. Seroprevalence of hepatitis A virus infection among sewage workers in the Parisian area, France, Eur J Epidemiol 1996; 12: 237-40